title: Targeting castration-resistant prostate cancer with monoclonal antibodies and constructs.
abstract: Antibodies administered either alone or in a unique construct that can enhance targeting, immunologic recognition and cell killing, remain an area of active interest for a variety of solid tumors. Prostate cancer has unique characteristics as a target for immune-mediated therapies, particularly since it has not only a wide array of antigens expressed on its cell surface, but also has an associated biomarker, which not only can monitor the disease status but also its response to therapy. A number of unique cell surface antigens, as well as internally mediated cell molecules, have shown their clinical activity and efficacy as prostate cancer treatments. The continued evolution of novel antibody-drug and antibody-imaging constructs will probably offer more efficient ways to deliver a therapeutic to the tumor and enhance imaging of active or treated sites of disease.
authors.affiliation: Genitourinary Oncology Service, Sidney Kimmel Center for Prostate & Urologic Cancers, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. slovins@mskcc.org.
authors.forename: Susan F
authors.initials: SF
authors.lastname: Slovin
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000037:antagonists & inhibitors* / Q000276:immunology; D006801:Humans; D018796:Immunoconjugates / Q000276:immunology / Q000627:therapeutic use; D008297:Male; D058990:Molecular Targeted Therapy / Q000379:methods*; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000276:immunology; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D018796:Immunoconjugates; D009363:Neoplasm Proteins